Grufity logoGrufity logo

NTLA

48.26USD-1.42(-2.86%)Market Closed

Intellia Therapeutics Inc

Market Summary

USD48.26-1.42Market Closed
-2.86%

NTLA Stock Price

RSI Chart

Valuation

Market Cap

4.1B

Price/Earnings

-10.26

Price/Sales

90.58

Price/Cashflow

-14.43

MarketCap/EBT

-49.09

Price/Sales

Profitability

EBT Margin

-204.35%

Return on Equity

-45.48%

Return on Assets

-36.06%

Fundamentals

Revenue

Revenue (TTM)

45.3M

Revenue Y/Y

114.2%

Revenue Q/Q

24.69%

Earnings

Earnings (TTM)

-400.4M

Earnings Y/Y

-46.32%

Earnings Q/Q

31.45%

Price Action

52 Week Range

37.08130.33
(Low)(High)

Last 7 days

-0.3%

Last 30 days

-10.7%

Last 90 days

-19.9%

Trailing 12 Months

-57.3%

Financial Health

Current Ratio

7.24

Investor Care

Shares Dilution (1Y)

3.44%

Diluted EPS (TTM)

-5.36

Peers (Alternatives to Intellia Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
7.33% 41.28%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
7.93% -48.43%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
-1.24% 15.25%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.45% 71.74%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
2.29% 10.96%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
16.60% 39.79%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
2.47% 48.37%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-7.28% 2.72%
-18.85
63.29
26.15% -23.38%
3.8B
-
40.88% -30.05%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-14.72% -55.15%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-13.15% -53.72%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
16.21% 132.25%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-11.05% -20.38%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
30.32% -65.42%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-6.48% -86.46%
-0.46
19.11
-77.61% 5.14%

Financials for Intellia Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue19.8%4538332742
  S&GA Expenses6.8%8580716052
  R&D Expenses9.7%355324230197176
Net Income-8.6%-400.43-368.56-267.89-228.85-185.04
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-7.7%1,1101,2031,2941,335672
  Current Assets2.3%895875769815549
    Cash Equivalents10.8%148133123335130
  Net PPE9.2%2624212019
  Current Liabilities-1.9%1241261269874
Shareholder's Equity-7.7%8819541,0401,107495
  Retained Earnings-11.8%-950.55-849.87-703.00-621.76-550.12
  Additional Paid-In Capital1.6%1,8411,8121,7461,7291,045
Accumulated Depreciation-26----
Shares Outstanding0.5%7676747468
Float-10,926----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-12.7%-284.56-252.45-225.03-210.60-174.14
  Share Based Compensation21.1%7259473828
Cashflow From Investing13.0%-415.68-477.76-550.78-602.58-357.18
Cashflow From Financing-0.2%724725737969300

Risks

What is the probability of a big loss on NTLA?

100%


Probability that Intellia Therapeutics stock will be more than 20% underwater in next one year

95%


Probability that Intellia Therapeutics stock will be more than 30% underwater in next one year.

72.3%


Probability that Intellia Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NTLA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on NTLA

18.1%


5-Year Cumulative Returns

40.7%


3-Year Cumulative Returns

What are the long-term rolling returns for NTLA?

FIve years rolling returns for Intellia Therapeutics.

Which funds bought or sold NTLA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
1,671,000
1,671,000
0.06%
2022-11-22
Capital Impact Advisors, LLC
-
-
-9,000
586,000
0.58%
2022-11-21
FourThought Financial, LLC
-
-
-18,000
2,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
REDUCED
-87.07
-1,342,000
218,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
329,000
4,954,000
0.01%
2022-11-16
Front Row Advisors LLC
NEW
-
6,000
6,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
36.01
255,000
797,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
246,000
246,000
-%
2022-11-15
Neuberger Berman Group LLC
ADDED
7.54
1,099,000
7,835,000
0.01%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
UNCHANGED
-
1,000
3,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying NTLA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NTLA

Intellia Therapeutics News

Investor's Business Daily

Cathie Wood Has Bet Big On These 10 Stocks.7 hours ago

NTLA Fair Value

Recent SEC filings of Intellia Therapeutics

View All Filings
Date Filed Form Type Document
Nov 14, 2022
8-K
Current Report
Nov 07, 2022
8-K
Current Report
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Sep 16, 2022
8-K
Current Report

Latest Insider Trading transactions for NTLA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-06-14
Crowley John F
ACQUIRED
-
-
5,197
-
2022-06-14
DORSA CAROLINE
ACQUIRED
-
-
5,197
-
2022-06-14
Bhanji Muna
ACQUIRED
-
-
2,014
-
2022-06-14
Cohen Fred E
ACQUIRED
-
-
5,197
-
2022-06-14
Keresty Georgia
ACQUIRED
-
-
5,197
-
2022-06-14
Verwiel Frank
ACQUIRED
-
-
5,197
-
2022-06-14
GOODMAN JESSE
ACQUIRED
-
-
5,197
-
2022-06-14
FORMELA JEAN FRANCOIS
ACQUIRED
-
-
5,197
-
2022-04-28
Bhanji Muna
ACQUIRED
-
-
7,954
-
2022-03-01
Lebwohl David
ACQUIRED
-
-
13,816
EVP, Chief Medical Officer

1–10 of 50

John M. Leonard
480
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Collaboration revenue$ 13,266$ 7,204$ 38,548$ 20,199
Type of Revenue [Extensible List]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Operating expenses:    
Research and development$ 96,651$ 60,486$ 319,945$ 158,646
General and administrative22,14518,71166,68048,988
Total operating expenses118,79679,197386,625207,634
Operating loss(105,530)(71,993)(348,077)(187,435)
Other (expense) income, net:    
Interest income1,9453493,188780
Loss from equity method investment(1,834)0(7,831)0
Change in fair value of contingent consideration(7,810)0(8,059)0
Total other (expense) income, net(7,699)349(12,702)780
Net loss$ (113,229)$ (71,644)$ (360,779)$ (186,655)
Net Loss Per Share, Basic$ (1.49)$ (0.97)$ (4.78)$ (2.68)
Net Loss Per Share, Diluted$ (1.49)$ (0.97)$ (4.78)$ (2.68)
Weighted average shares outstanding, basic76,04773,70675,54369,720
Weighted average shares outstanding, diluted76,04773,70675,54369,720
Other comprehensive loss:    
Unrealized gain (loss) on marketable securities$ 991$ (161)$ (5,069)$ (175)
Other comprehensive loss from equity method investment(805)0(1,667)0
Comprehensive loss$ (113,043)$ (71,805)$ (367,515)$ (186,830)

NTLA Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 141,194$ 123,406
Marketable securities687,000625,282
Accounts receivable ($0 million and $0.1 million, respectively, from related party)4,0232,031
Prepaid expenses and other current assets26,73018,584
Total current assets858,947769,303
Marketable securities - noncurrent20,533337,361
Property and equipment, net26,59720,968
Operating lease right-of-use assets101,29079,143
Equity method investment40,10258,131
Investments and other assets36,98929,558
Total Assets1,084,4581,294,464
Current Liabilities:  
Accounts payable4,3849,653
Accrued expenses ($1.0 million and $0 million, respectively, from related party)58,37943,309
Current portion of operating lease liability13,5519,112
Current portion of deferred revenue ($28.5 million and $34.2 million, respectively, from related party)54,81863,759
Total current liabilities131,132125,833
Deferred revenue, net of current portion ($0 million and $19.9 million, respectively, from related party)25,67863,476
Long-term operating lease liability84,09764,911
Contingent consideration liability18,6000
Commitments and contingencies (Note 6)
Stockholders’ Equity:  
Common stock, $0.0001 par value; 120,000,000 shares authorized; 76,587,947 and 74,485,883 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively87
Additional paid-in capital1,898,0911,745,870
Accumulated other comprehensive loss(9,368)(2,632)
Accumulated deficit(1,063,780)(703,001)
Total stockholders’ equity824,9511,040,244
Total Liabilities and Stockholders’ Equity$ 1,084,458$ 1,294,464